Ocugen(NASDAQ) OCGN

Ocugen, Inc. creates gene therapies to treat blindness. These medicines aim to repair or preserve retinal health. The company helps patients with rare eye diseases.

Saving Sight With Gene Therapy

• OCU400: Gene therapy that treats several forms of retinitis pigmentosa by resetting health in the retina; currently in late-stage clinical trials.
• OCU410: Therapy designed to treat geographic atrophy and dry age-related macular degeneration using a single sub-retinal injection.
• OCU410ST: Specialized treatment for Stargardt disease that modulates lipid metabolism and oxidative stress to restore eye health.
• OCU200: Fusion protein undergoing early study for vascular complications like diabetic macular edema and wet macular degeneration.
• OCU500: Inhaled vaccine for COVID-19 being developed in collaboration with the National Institute of Allergy and Infectious Diseases.

Moving Toward the Finish Line

• Completed enrollment for the Phase 3 liMeliGhT trial of OCU400 in 2026 with topline data expected in 2027.
• Received Regenerative Medicine Advanced Therapy designation from the FDA for OCU410 in July 2026 to treat geographic atrophy.
• Finished dosing for the Phase 2/3 pivotal trial of OCU410ST for Stargardt disease in April 2026.
• Secured $130.0 million through a private offering of convertible notes in May 2026 to fund clinical development.

A New Way to Fix Genes

The company uses a modifier gene therapy platform that targets gene networks rather than individual mutations. This gene-agnostic approach allows one treatment to potentially help patients with many different genetic causes for the same disease.

Measuring the Progress

• Net loss reached $24.9 million for the three-month period ended June 30, 2026, compared to $14.7 million in 2025.
• Collaborative arrangement revenue rose to $3.0 million for the six-month period ended June 30, 2026, up $0.2 million year over year.
• Research and development costs hit $21.9 million for the six-month period ended June 30, 2026, up $4.0 million year over year.
• Cash and cash equivalents were $100.1 million as of June 30, 2026.
• Accumulated deficit grew to $452.1 million as of June 30, 2026, due to ongoing clinical research expenses.

Focus on Clinical Results

Ocugen has transitioned from a research-stage startup to a clinical-stage biotechnology firm with several late-stage trials. While development costs remain high, its novel platform offers a broad way to address diverse blinding diseases.